Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Conditions
Interventions
- DRUG: Dabigatran
- DRUG: Rivaroxaban
- DRUG: Apixaban
Sponsor
Ottawa Heart Institute Research Corporation
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]